Sign inJoin free

Watch / Reporting Season

15 years of blood, sweat and tears now paying dividends

24 Feb 20224:42

15 years of blood, sweat and tears now paying dividends

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Imricor (IMR) CEO Steve Wedan says the past 12 months have been monumental for the company, despite COVID headwinds. The company added five new sites in Europe, brining the total to 14. The company also successfully raised $16.5M dollars to execute its strategic plan which includes growing its installed base, expanding geographies and expanding its indications. US regulatory approval has always been a hinderance, but Steve explains early commercialisation in Europe was all part of the a cooperative research and development agreement. Imricor is now working with the FDA on an investigational device exemption, which is currently in a review process, and is a precursor to clinical trials. Steve anticipates FDA approval will come in 2023. Listen to Steve's take on whether Imricor is a takeover target, and whether he would bite. Shares in the medtech company moved higher in early Thursday trade on the news.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy